

FIP1L1-PDGFR α Fusion Transcript Detection

RNA-PCR

Indication

For determining the presence or absence of the FIP1L1-PDGFR α fusion transcript produced by a gene fusion that is seen in some cases of hypereosinophilic syndrome and systemic mast cell disease. This test is used for residual disease detection following therapy.

Methodology

RNA is analyzed for FIP1L1-PDGFR α fusions by reverse transcription nested PCR.

Test Parameters

A control RNA sequence is amplified in parallel as a control for sample quality.

Turnaround Time

Five to 10 working days

Sample Requirements

- 10 ml peripheral blood in purple top tube (EDTA Vacutainer), sent by overnight express mail
or
- 2-5 ml of bone marrow aspirate in purple top tube (EDTA Vacutainer), sent by overnight express mail
or
- 10 μ g of purified RNA or cDNA, sent by overnight express mail on dry ice

CPT Codes

83891 (RNA isolation), 83902, 83898, 83909, 83912

[Make appointment](#)[Confirm/change/cancel appt](#)[Find location](#)[Home](#) [About Us](#) [Site Directory](#) [Privacy Policy](#)[Patient Service Centers](#)[Healthcare IT](#)[Test Menu](#)[Interpretive Guide](#)

To search for a specific test, select your regional laboratory

WA – Seattle 1737 Airport Way S (206) 623-8100 (SEA)

E-PRESCRIBING CAN HELP YOU QUALIFY FOR THE CMS 2% INCENTIVE PAYMENT

SEARCH

[Search Help](#)

GENERAL COLLECTION INFORMATION

[Collection Tubes](#)
[Proper Order of Draw](#)

NEW TESTS

[New Tests](#)

BROWSE BY TEST NAME

[A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#)
[G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#)
[M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#)
[S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#)
[Y](#) | [Z](#)

FISH, HES/Leukemia, 4q12 Rearrangement (FIP1L1-PDGFR) 10

CPT Code(s): 88271 (x3), 88275, 88291

This test was developed and its performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

Preferred Specimen(s)

3 mL bone marrow in transport media

Minimum Volume

1 mL

Alternate Specimen(s)

Bone marrow **or** whole blood collected in a sodium heparin (green-top), sodium heparin blue-top) or sodium heparin lead-free (tan-top) tube

Instructions

Bone marrow: 1-3 mL in transport medium (preferred) or sodium heparin (green-top)

Whole blood: 3-5 mL collected in a sodium heparin (green-top) tube

Ship at room temperature. **Do not freeze.**

Specimen viability decreases during transit. Send specimen to testing lab for viability determination. **Do not reject.**

Transport Container

Transport media

Transport Temperature

Room temperature

Specimen Stability

Room temperature: See Instructions

Refrigerated: See Instructions

Frozen: Unacceptable

Methodology

Fluorescence in situ Hybridization (FISH)

Performing Laboratory

Quest Diagnostics Nichols Institute-San Juan Capistrano, CA
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042

Setup Schedule

Set up: Mon-Sat; Report available: 7 days

Reference Range(s)

See Medical Report

Clinical Significance

FIP1L1-PDGFRa fusion (rearrangement of 4q12; interstitial deletion of CHIC2 region) observed in diverse eosinophilia-associated hematologic disorders. The cases with FIP1L1-PDGFRa fusion show an excellent response to the tyrosine kinase inhibitor imatinib mesylate (Metzgeroth et al, 2007)

(The CPT codes provided are based on AMA guidelines and are for informational purposes only. Coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.)

Go to: [HOME](#) | [Healthcare Professionals](#) | [Patients and Consumers](#) | [About Our Company](#) | [Mobile Website](#)

Quest, Quest Diagnostics, the associated logo, Nichols Institute and all associated Quest Diagnostics marks are trademarks of Quest Diagnostics. All third party marks — ®' and ™' — are the property of their respective owners. Quest Diagnostics Incorporated. All rights reserved.